Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00784823 · ClinicalTrials.gov registry record · Phase 1
Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Hackensack Meridian Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT00784823: Completed Phase 1 study of Multiple Myeloma, sponsored by Hackensack Meridian Health.
NCT00784823 is a Phase 1 study of Multiple Myeloma that has completed, run by Hackensack Meridian Health. The registered enrollment target is 32 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00784823, a Phase 1 study of Multiple Myeloma, has completed, sponsored by Hackensack Meridian Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the tolerance and potential efficacy of combining dose intense melphalan with escalating doses of bortezomib in patients with multiple myeloma undergoing autologous stem cell transplantation.
Conditions Studied
Interventions
- DRUG Melphalan
- DRUG Bortezomib 1 mg/m2
- DRUG Bortezomib 1.3 mg/m2
- DRUG Bortezomib 1.6 mg/m2
Study Locations (1)
New Jersey
- Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2007-01 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00784823
The ClinicalTrials.gov registry entry for NCT00784823 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower). The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Melphalan is the first listed.
NCT00784823 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00784823 about?
NCT00784823 is a clinical study titled "Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma". The purpose of this study is to determine the tolerance and potential efficacy of combining dose intense melphalan with escalating doses of bortezomib in patients with multiple myeloma undergoing autologous stem cell transplantation.
What is the current status of trial NCT00784823?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2007-01. Estimated completion is 2013-12.
What conditions does trial NCT00784823 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00784823?
The interventions under investigation include: Melphalan (DRUG), Bortezomib 1 mg/m2 (DRUG), Bortezomib 1.3 mg/m2 (DRUG), Bortezomib 1.6 mg/m2 (DRUG).
Who is sponsoring clinical trial NCT00784823?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00784823 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.